Results 51 to 60 of about 40,760 (162)
Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review
Advances in Respiratory MedicineNirmatrelvir/Ritonavir is an oral treatment for mild to moderate COVID-19 cases with a high risk for a severe course of the disease. For this paper, a comprehensive literature review was performed, leading to a summary of currently available data on ...
Sydney Paltra, Tim O. F. Conrad
doaj +1 more source
BMC Nephrology, 2023 Background Despite vaccination coronavirus disease 2019 (COVID-19)-associated mortality caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains high in kidney transplant recipients.
Johanna Schneider +5 more
doaj +1 more source
Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients
Hepatology Research, EarlyView.ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki +10 more
wiley +1 more source
The impact of accumulating immune adaptation in circulating strains of HIV‐1
HIV Medicine, EarlyView.Abstract Background Mutations in human immunodeficiency virus type 1 (HIV‐1) enable the virus to evade recognition and killing by human leucocyte antigen (HLA)‐restricted T cells. These viral adaptations are specific to the HLA type of individuals and are therefore evident as HLA allele‐HIV sequence associations at the population level. Most studies of
Marwah Al‐kaabi +7 more
wiley +1 more source
HIV Medicine, EarlyView.Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux +15 more
wiley +1 more source
PharmaceuticsPaxlovid®, a co-packaged medication comprised of separate tablets containing two active ingredients, nirmatrelvir (NRV) and ritonavir (RTV), exhibits good effectiveness against coronavirus disease 2019 (COVID-19). However, the size of the NRV/RTV tablets
Lili Wang +7 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 891-904, April 2026.Limited evidence exists synthesizing the risk of acute kidney injury (AKI) associated with the concomitant administration of multiple nephrotoxic drugs, and even less examining the concept of nephrotoxic burden. The objective of this scoping review was to (1) identify definitions of nephrotoxic burden; (2) methods used to quantify (use of calculations)
Wafa Alatawi +6 more
wiley +1 more source
Clinical and Translational Science, Volume 19, Issue 4, April 2026.ABSTRACT Molnupiravir is an orally administered prodrug of β‐D‐N4‐hydroxycytidine (NHC) that is conditionally approved in China for the treatment of mild to moderate COVID‐19 in nonhospitalized adults at high risk of disease progression. Molnupiravir is rapidly absorbed and hydrolyzed to deliver NHC into systemic circulation.
Jixiang Zhu +10 more
wiley +1 more source
Health Science Reports, Volume 9, Issue 3, March 2026.ABSTRACT Background and Aims This study aimed to compare the clinical symptoms of mild COVID‐19 and influenza during a period when both diseases circulated in the 2023–2024 influenza season in Japan. Methods Outpatients diagnosed with COVID‐19, influenza A, or influenza B by antigen test kits at 10 medical facilities in Japan were enrolled.
Takuma Bando +10 more
wiley +1 more source